More tools:Markets·Screener·Research·Chat

Purple Biotech Ltd. American Depositary Shares (PPBT) Financial Statements

Purple Biotech Ltd. American Depositary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00B3L3T26
XNAS · usd
1.84▲ 0.04 (2.22%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1.80
Day's Range1.70 – 1.84
52-Week Range0.41 – 5.38
Volume131.8K
Avg Volume2.7M
Share Statistics
Shares Outstanding
Employees10
ExchangeXNAS
Listed2015-11-20
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Purple Biotech Ltd. American Depositary Shares (PPBT)
What is Purple Biotech Ltd. American Depositary Shares's Market Cap?
Purple Biotech Ltd. American Depositary Shares's Market Cap is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Purple Biotech Ltd. American Depositary Shares's Enterprise Value?
Purple Biotech Ltd. American Depositary Shares's Enterprise Value is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Purple Biotech Ltd. American Depositary Shares's Net Income (TTM)?
Purple Biotech Ltd. American Depositary Shares's Net Income (TTM) is -$26.5M, based on as-reported figures from SEC (XBRL) filings.
What is Purple Biotech Ltd. American Depositary Shares's Diluted EPS (TTM)?
Purple Biotech Ltd. American Depositary Shares's Diluted EPS (TTM) is -0.01, based on as-reported figures from SEC (XBRL) filings.
What is Purple Biotech Ltd. American Depositary Shares's Net Debt?
Purple Biotech Ltd. American Depositary Shares's Net Debt is -$8.7M, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Research and development expenses
General and administrative expenses
Impairment loss
Operating loss
Change in fair value of warrants
Finance expenses
Finance income
Finance income, net
Loss for the year
Items that will be transferred to profit or loss:
Loss (profit) from cash flow hedges—
Total comprehensive loss for the year
Loss attributable to:
Owners of the Company
Non-controlling interests
Loss for the year
Total comprehensive loss attributable to:
Owners of the Company
Non-controlling interests
Total comprehensive loss for the year
Loss per share information
Basic loss per Share – USD (in Dollars per share)
Diluted loss per Share – USD (in Dollars per share)